Orthofix Medical Inc. operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions. This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations. The Global Orthopedics segment offers products and solutions that allow physicians to treat various orthopedic conditions related to limb reconstruction and deformity correction unrelated to the spine. This segment designs, develops, and markets external and internal fixation orthopedic products that are coupled with enabling digital technologies to serve the complete patient treatment pathway. It sells its products through distributors and sales representatives to hospitals, healthcare organizations, and healthcare providers. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.
Merger Momentum | Orthofix's integration with SeaSpine drives growth, with Q2 revenues surpassing expectations and improved guidance for 2024 |
Segment Strengths | Bone Growth Therapies leads with double-digit growth, while Spinal Implants and Global Orthopedics show steady progress |
Financial Turnaround | Orthofix anticipates positive free cash flow in H2 2024, earlier than expected, signaling improved operational efficiency |
Analyst Perspectives | Roth MKM sets $20 price target, while JMP Securities maintains Market Perform rating, reflecting mixed outlook on profitability |
Metrics to compare | OFIX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipOFIXPeersSector | |
---|---|---|---|---|
P/E Ratio | −6.1x | −8.5x | −0.7x | |
PEG Ratio | −0.25 | −0.08 | 0.00 | |
Price/Book | 1.4x | 3.4x | 2.6x | |
Price / LTM Sales | 0.9x | 3.3x | 3.2x | |
Upside (Analyst Target) | 24.1% | 42.2% | 46.4% | |
Fair Value Upside | Unlock | −4.3% | 6.9% | Unlock |